Hormonal / Allergy was Amneal Pharmaceuticals’s largest product and service line in fiscal 2021, bringing in $427.08M of $1.71B (25%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|
| Central Nervous System | $659.26M | $422.41M | $381.11M |
| Hormonal / Allergy | — | — | $427.08M |
| Hormonal/Allergy | $410.21M | $410.21M | — |
| Distribution | — | $161.67M | $192.92M |
| Cardiovascular System | $117.07M | $114.23M | $141.87M |
| Government Label | — | $104.05M | $118.38M |
| Other Therapeutic Classes | — | $102.72M | $69.93M |
| Oncology | $62.72M | $61.11M | $103.33M |
| Gastroenterology | $47.01M | $78.17M | $76.50M |
| Dermatology | $60.19M | $58.17M | $55.47M |
| Metabolic Disease / Endocrine | — | — | $38.46M |
| Metabolic Disease/Endocrine | $56.68M | $45.00M | — |
| Other | $91.06M | $9.47M | $12.54M |
| Respiratory | $34.92M | $37.39M | $35.97M |
| Anti-Infective | $36.32M | $40.38M | $30.50M |
| Institutional | — | $18.55M | $25.18M |
| Antiviral | — | $25.72M | $4.83M |
| Antiviral (1) | $27.49M | — | — |
| Total | $1.60B | $1.69B | $1.71B |
Amneal Pharmaceuticals brought in $1.71B from its 15 product and service lines in fiscal 2021, the year ended December 31, 2021. Amneal Pharmaceuticals regrouped these lines after fiscal 2020, so the total does not compare directly with that year's $1.69B. Hormonal / Allergy was the largest at $427.08M (24.9%), ahead of Central Nervous System at $381.11M (22.2%) and Distribution at $192.92M (11.3%). The other 12 lines brought in $712.94M combined.
Compared with fiscal 2020, Oncology grew fastest, up 69.1% to $103.33M, while Other Therapeutic Classes fell the most, down 31.9% to $69.93M.
Amneal Pharmaceuticals began breaking out Hormonal / Allergy in fiscal 2021, Distribution in fiscal 2020, Government Label in fiscal 2020 and Other Therapeutic Classes in fiscal 2020. Amneal Pharmaceuticals stopped reporting Hormonal/Allergy ($410.21M in fiscal 2020), Metabolic Disease/Endocrine ($45.00M in fiscal 2020) and Antiviral (1) ($27.49M in fiscal 2019) as separate lines.
United States was Amneal Pharmaceuticals’s largest region in fiscal 2021, bringing in $761.86M of $763.16M (100%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|
| United States | — | — | $525.13M | $761.86M | |
| Us | $528.92M | $686.75M | — | — | |
| International & Other | $59.99M | $23.46M | $2.33M | $1.30M | |
| International | — | — | — | — | |
| Total | $588.92M | $710.21M | $527.46M | $763.16M |
Amneal Pharmaceuticals brought in $763.16M from its two regions in fiscal 2021, the year ended December 31, 2021. That is less than the $1.71B it reports by product and service, so these regions do not cover all of its revenue. United States was the largest at $761.86M (99.8%), ahead of International & Other at $1.30M (0.2%).
Amneal Pharmaceuticals began breaking out United States in fiscal 2020, when it brought in $525.13M. Amneal Pharmaceuticals stopped reporting Us as a separate region after fiscal 2019, when it brought in $686.75M.
Amneal Pharmaceuticals (AMRX) reports its revenue by product and service and by geography. In fiscal 2021, Hormonal / Allergy was its largest product and service line, bringing in $427.08M (24.9% of the total), followed by Central Nervous System at $381.11M (22.2%).
Hormonal / Allergy was Amneal Pharmaceuticals' largest product and service line in fiscal 2021, bringing in $427.08M, or 24.9% of the $1.71B total across its 15 product and service lines.
United States was Amneal Pharmaceuticals' largest region in fiscal 2021, bringing in $761.86M, or 99.8% of the $763.16M total across its two regions.
Every figure comes from Amneal Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Amneal Pharmaceuticals gives it, and years follow its fiscal calendar.
Amneal Pharmaceuticals' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2021. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.